The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: Results from a controlled study
G. Saggese et al., The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: Results from a controlled study, J CLIN END, 86(5), 2001, pp. 1900-1904
To assess whether delaying puberty may improve final height in GH-deficient
children with a poor height prediction at early puberty, we studied 24 gir
ls with isolated GH deficiency until they reached their final height, in a
controlled trial. Patients were taking recombinant human GH (r-hGH) substit
utive therapy from 2.1 +/- 0.5 yr (0.1 IU/kg day sc) before entering the st
udy, without showing any improvement in height prediction (149.6 +/- 2.9 vs
.150.3 +/- 2.2 cm) on entering puberty. Fourteen girls agreed to add a GnRH
agonist (GnRHa) to r-hGH, whereas the remaining 10 decided against it and
served as controls. At the start of the study, girls treated with or withou
t GnRHa had similar auxological characteristics (bone age, 10.9 +/- 0.6 vs.
10.7 +/- 1.3 yr; height SD score for chronological age, -1.87 +/- 0.3 vs.
-1.82 +/- 0.2), including pubertal development. The GnRHa (long-acting D-Tr
p-6-GnRH) was given at 60 mug/kg im every 28 days for 1.9 +/- 0.9 yr, then
patients continued the r-hGH at the same dosage (3.1 +/- 0.7 yr). At the en
d of the study, bone age was 16.2 +/- 0.3 yr in GnRHa-treated girls and 16.
6 +/- 0.9 yr in controls. Bone maturation was significantly slower during G
nRHa (1.4 +/- 0.2 yr), and height so score for bone age improved (-0.31 +/-
0.3) in comparison with controls (2.6 +/- 0.4 yr and -1.35 +/- 0.3 SD scor
e; P < 0.001 and P < 0.0001, respectively). As a result, girls given the co
mbined therapy reached a final height higher than that of controls (height
SD score, -0.39 +/- 0.5 vs. -1.45 +/- 0.2; P < 0.0001) and also higher than
their midparental height(-1.1 +/- 0.5; P < 0.0005). Controls reached their
midparental height. In conclusion, our results demonstrate that slowing pu
bertal development with the administration of GnRHa for a limited time may
improve final height in GH-deficient girls selected because of a poor heigh
t prediction at early puberty.